[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Segawa Y, Hotta K, Umemura S, Fujiwara Y, Shinkai T, Ueoka H, Takigawa N, Tabata M, Kiura K, Tanimoto M: Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer; 2006 Oct 15;107(8):1866-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
  • BACKGROUND: The risk factors for the development of acquired resistance in nonsmall cell lung cancer (NSCLC) patients responding to gefitinib are unclear.
  • The current study assessed clinicopathologic factors affecting acquired resistance to gefitinib in previously treated patients with advanced NSCLC.
  • METHODS: Between 2000 and 2004, 197 consecutive Japanese patients with advanced NSCLC underwent treatment with gefitinib.
  • Of these patients, 56 who had continued gefitinib treatment without disease progression for at least 6 months were included in the study.
  • RESULTS: At a median follow-up time of 21.6 months (range, 7.7-59.7 months), the median time to disease progression was 19.5 months, with progression-free survival rates of 68.5% at 1 year, 33.6% at 2 years, and 21.2% at 3 years.
  • In a multivariate analysis using a Cox regression model, baseline brain metastasis was the strongest prognostic factor affecting acquired resistance to gefitinib (hazards ratio, 2.14; 95% confidence interval, 1.10- 4.17 [P = .025]).
  • In addition, a decreased baseline hemoglobin level (P = .074) and the administration of >1 chemotherapy regimen before gefitinib treatment (P = .069) tended to be significant negative prognostic factors.
  • CONCLUSIONS: In patients undergoing treatment with gefitinib, the presence of brain metastasis was strongly associated with the emergence of acquired resistance in the current series of NSCLC patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Resistance, Neoplasm. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Disease Progression. Disease-Free Survival. Female. Humans. Japan. Male. Middle Aged. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16967452.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


2. Sidani CA, Ballourah W, El Dassouki M, Muwakkit S, Dabbous I, Dahoui H, Al-Kutoubi A, Abboud MR: Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis. Am J Hematol; 2008 Oct;83(10):818-20
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis.
  • A 21-year-old man with homozygous sickle cell disease maintained on hydroxyurea for 1 year developed thrombosis of the superior sagittal, right transverse, and right sigmoid dural sinuses with a large venous infarct.
  • Investigation did not reveal any inherited or acquired hypercoagulable state.
  • This patient however had consistently elevated hemoglobin levels both at the time of the initial event and on follow up.
  • One year later he developed symptomatic avascular necrosis of the right hip.
  • High hemoglobin levels resulting from hydroxyurea therapy may have contributed to development of complications in this patient.
  • [MeSH-major] Anemia, Sickle Cell / drug therapy. Antisickling Agents / therapeutic use. Hemoglobins / analysis. Hydroxyurea / therapeutic use. Stroke. Thrombolytic Therapy
  • [MeSH-minor] Adult. Brain Infarction / radiography. Dura Mater / blood supply. Follow-Up Studies. Hip / pathology. Hip / radiography. Homozygote. Humans. Male. Osteonecrosis / complications. Osteonecrosis / pathology. Osteonecrosis / radiography. Sinus Thrombosis, Intracranial / drug therapy. Sinus Thrombosis, Intracranial / radiography. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Sickle Cell Disease.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18756541.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antisickling Agents; 0 / Hemoglobins; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


3. Cantrell RA, Sinkala M, Megazinni K, Lawson-Marriott S, Washington S, Chi BH, Tambatamba-Chapula B, Levy J, Stringer EM, Mulenga L, Stringer JS: A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia. J Acquir Immune Defic Syndr; 2008 Oct 1;49(2):190-5
HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia.
  • BACKGROUND: The provision of food supplementation to food-insecure patients initiating antiretroviral therapy (ART) may improve adherence to medications.
  • The analysis compared adherence (assessed by medication possession ratio), CD4, and weight gain outcomes among food-insecure patients enrolled at the food clinics with those enrolled at the control clinics.
  • Food supplementation was associated with better adherence to therapy.
  • Two hundred fifty-eight of 366 (70%) patients in the food group achieved a medication possession ratio of 95% or greater versus 79 of 166 (48%) among controls (relative risk = 1.5; 95% confidence interval: 1.2 to 1.8).
  • This finding was unchanged after adjustment for sex, age, baseline CD4 count, baseline World Health Organization stage, and baseline hemoglobin.
  • CONCLUSIONS: This analysis suggests that providing food to food-insecure patients initiating ART is feasible and may improve adherence to medication.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD004536 [17636766.001]
  • [Cites] Br J Nutr. 2007 Jul;98(1):211-7 [17381879.001]
  • [Cites] Manag Care. 2001 Feb;10(2):42-5 [11236643.001]
  • [Cites] AIDS. 2003 Jun 13;17(9):1369-75 [12799558.001]
  • [Cites] N Engl J Med. 2004 Jul 1;351(1):23-32 [15229304.001]
  • [Cites] N Engl J Med. 2004 Jul 1;351(1):78-80 [15229312.001]
  • [Cites] Metabolism. 1990 Nov;39(11):1186-90 [2233280.001]
  • [Cites] Am J Clin Nutr. 1991 Feb;53(2):437-41 [1989410.001]
  • [Cites] Am J Clin Nutr. 1992 Feb;55(2):455-60 [1734684.001]
  • [Cites] J Clin Epidemiol. 1996 Apr;49(4):435-9 [8621994.001]
  • [Cites] J Assoc Nurses AIDS Care. 1997 May-Jun;8(3):24-32 [9249667.001]
  • [Cites] JAMA. 1998 Nov 18;280(19):1690-1 [9832001.001]
  • [Cites] Br J Nutr. 1999 Mar;81(3):181-9 [10434844.001]
  • [Cites] AIDS. 1999 Jul 30;13(11):1351-7 [10449288.001]
  • [Cites] J Nutr. 2005 Apr;135(4):938-44 [15795466.001]
  • [Cites] Am J Manag Care. 2005 Jul;11(7):449-57 [16044982.001]
  • [Cites] AIDS. 2006 May 12;20(8):1163-9 [16691068.001]
  • [Cites] JAMA. 2006 Aug 9;296(6):679-90 [16896111.001]
  • [Cites] JAMA. 2006 Aug 16;296(7):782-93 [16905784.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84 [16878045.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1587-94 [17084759.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2355-60 [17117022.001]
  • [Cites] JAMA. 2007 Oct 24;298(16):1888-99 [17954540.001]
  • (PMID = 18769349.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / K01 TW 06670; United States / FIC NIH HHS / TW / D43 TW 001035; United States / FIC NIH HHS / TW / K01 TW 05708; United States / FIC NIH HHS / TW / K01 TW005708; United States / FIC NIH HHS / TW / K01 TW006670; United States / FIC NIH HHS / TW / D43 TW001035
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS528808; NLM/ PMC3847664
  •  go-up   go-down


Advertisement
4. Larakeb AS, Evrard S, Louillet F, Kwon T, Djaffar H, Llanas B, DeschĂȘnes G, Hurtaud-Roux MF, Baudouin V: Acute renal cortical necrosis due to acquired antiprotein S antibodies. Pediatr Nephrol; 2009 Jan;24(1):207-9
MedlinePlus Health Information. consumer health - Chickenpox.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal cortical necrosis due to acquired antiprotein S antibodies.
  • Although varicella is a common disease of childhood, renal complications are quite rare.
  • We report here the interesting case of a-22 month-old boy exhibiting renal cortical necrosis related to an acquired protein S deficiency following varicella.
  • Ten days after the vesicle eruption appearance, he presented with ecchymosed heels, oligoanuric kidney failure, anemia [hemoglobin (Hb) 78 g/L], schizocytosis (2.5%), but normal platelet count.
  • All together, these features suggested acquired protein S deficiency secondary to varicella.
  • Anticoagulation therapy in addition with plasmapheresis and steroid pulses allowed a dramatic decrease in the antibodies against protein S and recovery of normal protein S activity.
  • Undelayed diagnosis and treatment did not avoid kidney insufficiency but prevented life-threatening complications.
  • [MeSH-minor] Anticoagulants / therapeutic use. Enoxaparin / therapeutic use. Glucocorticoids / administration & dosage. Glucocorticoids / therapeutic use. Humans. Infant. Kidney / diagnostic imaging. Kidney / pathology. Magnetic Resonance Imaging. Male. Plasmapheresis. Pulse Therapy, Drug. Treatment Outcome. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 1995 Sep;127(3):355-63 [7658262.001]
  • [Cites] Transfus Sci. 1998 Sep;19(3):253-9 [10351137.001]
  • [Cites] J Pediatr. 1996 Mar;128(3):319-23 [8774497.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):413-6 [12142795.001]
  • [Cites] Pediatr Res. 2001 Sep;50(3):345-52 [11518821.001]
  • [Cites] Br J Dermatol. 1992 Jul;127(1):30-2 [1386247.001]
  • [Cites] J Child Neurol. 2005 May;20(5):441-4 [15968930.001]
  • [Cites] Ann Hematol. 2006 Jan;85(1):64-5 [16132907.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1753-7 [8497285.001]
  • [Cites] J Thromb Haemost. 2005 Jun;3(6):1243-9 [15946215.001]
  • (PMID = 18777044.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Autoantibodies; 0 / Enoxaparin; 0 / Glucocorticoids; 0 / Protein S
  •  go-up   go-down


5. Lee J, El-Abaddi N, Duke A, Cerussi AE, Brenner M, Tromberg BJ: Noninvasive in vivo monitoring of methemoglobin formation and reduction with broadband diffuse optical spectroscopy. J Appl Physiol (1985); 2006 Feb;100(2):615-22
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Broadband DOS combines multifrequency frequency-domain photon migration (FDPM) with time-independent near infrared (NIR) spectroscopy to quantitatively measure bulk tissue absorption and scattering spectra between 600 nm and 1,000 nm.
  • Tissue concentrations (denoted by brackets) of methemoglobin ([MetHb]), deoxyhemoglobin ([Hb-R]), and oxyhemoglobin ([HbO2]) were determined from absorption spectra acquired in "real time" during nitrite infusions in nine pathogen-free New Zealand White rabbits.
  • As little as 30 nM [MetHb] changes were detected for levels of [MetHb] that ranged from 0.80 to 5.72 microM, representing 2.2 to 14.9% of the total hemoglobin content (%MetHb).
  • As little as 10 nM changes in [MB] were detectable at levels of up to 150 nM in tissue.
  • Our results demonstrate, for the first time, the ability of broadband DOS to noninvasively quantify real-time changes in [MetHb] and four additional chromophore concentrations ([Hb-R], [HbO2], [H2O], and [MB]) despite significant overlapping spectral features.
  • These techniques are expected to be useful in evaluating dynamics of drug delivery and therapeutic efficacy in blood chemistry, human, and preclinical animal models.
  • [MeSH-minor] Animals. Disease Models, Animal. Hemoglobins / metabolism. Kinetics. Methemoglobinemia / chemically induced. Methemoglobinemia / drug therapy. Methemoglobinemia / metabolism. Methylene Blue / administration & dosage. Methylene Blue / pharmacokinetics. Oxidation-Reduction. Oxyhemoglobins / metabolism. Photons. Rabbits. Scattering, Radiation. Sodium Nitrite

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • Hazardous Substances Data Bank. SODIUM NITRITE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16223982.001).
  • [ISSN] 8750-7587
  • [Journal-full-title] Journal of applied physiology (Bethesda, Md. : 1985)
  • [ISO-abbreviation] J. Appl. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Oxyhemoglobins; 9008-02-0 / deoxyhemoglobin; 9008-37-1 / Methemoglobin; M0KG633D4F / Sodium Nitrite; T42P99266K / Methylene Blue
  •  go-up   go-down


6. Nagayama N, Shishido Y, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Komatsu H, Yotsumoto H: [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid]. Kekkaku; 2004 May;79(5):341-8
Hazardous Substances Data Bank. ISONIAZID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].
  • OBJECTIVES: To examine the incidence rate by age and gender of leukopenia caused by chemotherapy including rifampicin (RFP) and isoniazid (INH), and to study the relationships between the leukopenia and the hepatic side effect or other haematological disorders such as thrombocytopenia.
  • SUBJECTS: Out of the tuberculosis patients who were admitted to our hospital in 1987-88, 1991-92, and 1996-2000, 1,525 patients (1,153 men, 372 women) were chosen for our study who had the white blood cell counts (WBC) in the peripheral blood more than 3,000/mm3 before chemotherapy, and underwent haematologic examination at least twice within 3 months after starting chemotherapy.
  • 1) WBC became less than 3,000/mm3 during chemotherapy for patients with pre-treatment WBC more than 4,000/mm3, or 2) WBC decreased more than 1,000/mm3 in patients with pre-treatment WBC between 3,000 and 4,000/mm3.
  • The incidence rates of leukopenia by age, gender, and regimens of chemotherapy were calculated.
  • For each patient with leukopenia, a patient with the same admission year, same gender, same regimen of chemotherapy, and the nearest age was chosen as a control patient.
  • The changes in counts of white blood cell, granulocyte, and platelet, in hemoglobin concentration, and in hepatic enzyme levels before and during chemotherapy were compared between the leukopenia and the control groups.
  • The chemotherapy was continued in 30 patients after the appearance of leukopenia, and the natural recovery from leukopenia was seen in 19 patients, while the leukopenic state lasted during the chemotherapy in the remaining 11 patients.
  • In two patients who exhibited agranulocytosis all drugs were discontinued.
  • In the remaining 4 patients one or more drugs were discontinued. (2) Case-control study between leukopenia (N = 34) and the control (N = 34) groups There were no differences in age, sputum culture positivity on admission, degree of roentgenographic extent of the disease, ratio of cavity formation, and quantity of daily doses between the two groups.
  • There was also no difference between the days until leukopenia appeared after starting chemotherapy (47.6 +/- 29.5 days) in the leukopenia group, and the days until WBC count became minimum within 3 months after starting chemotherapy (41.7 +/- 21.0 days) in the control group.
  • Before the starting chemotherapy, the counts of WBC (7,230 +/- 1,530 vs 5,500 +/- 1,510/mm3, p < 0.001), neutrophil (5,230 +/- 1,450 vs 4,320 +/- 1,620/mm3, p < 0.05), lymphocyte (1,440 +/- 830 vs 830 +/- 440/mm3, p < 0.001) and platelet (34.9 +/- 12.2 vs 24.1 +/- 6.4 x 10(4)/mm3, p < 0.001) in the peripheral blood and the globulin level (3.71 +/- 0.61 vs 3.35 +/- 0.61 g/dl, p < 0.05) in the serum were significantly higher in the control group than in the leukopenia group.
  • The decrements in the counts of WBC and granulocyte during chemotherapy were larger in the leukopenia group than in the control group (delta WBC: 2,880 +/- 1,530 vs 1,910 +/- 1,520/mm3, and delta Neut: 2,840 +/- 1,510 vs 1,820 +/- 1,380/mm3, p = 0.01, respectively), but the counts of lymphocyte were similar in both groups.
  • The levels in the serum of hepatic enzymes such as AST, ALT, and gamma-GTP (gamma-glutamyl aminotransferase) increased during chemotherapy in the leukopenia group, while decreased in the control group, and the facts indicate that in the former not only bone marrow cells but also hepatic cells were impaired by anti-tuberculosis drugs.
  • CONSIDERATIONS: Leukopenia may occur in the course of treatment with anti-tuberculosis drugs, but it is not necessary to stop the chemotherapy immediately, because the WBC count recovers spontaneously or remains under stable leukopenic state during chemotherapy in most cases.
  • But when leukopenia appears, the peripheral blood counts must be checked cautiously, and the chemotherapy should be stopped if the WBC count progressively decreases.
  • The patients who showed leukopenia due to anti-tuberculosis drugs may have had weaker natural and acquired (cell-mediated) immunologic response to tuberculosis infection, and more vulnerable bone marrow cells and hepatic cells to anti-tuberculosis drugs than the control.

  • Hazardous Substances Data Bank. RIFAMPIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15211874.001).
  • [ISSN] 0022-9776
  • [Journal-full-title] Kekkaku : [Tuberculosis]
  • [ISO-abbreviation] Kekkaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antitubercular Agents; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin
  •  go-up   go-down


7. Chi BH, Giganti M, Mulenga PL, Limbada M, Reid SE, Mutale W, Stringer JS: CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr; 2009 Sep 1;52(1):125-31
HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.
  • INTRODUCTION: Where virologic monitoring is not routinely available, immunologic criteria are commonly used to determine treatment failure while on antiretroviral therapy (ART).
  • We used Cox proportional hazards models that accounted for different strata of baseline CD4 counts and adjusted for age, sex, clinical stage, tuberculosis coinfection, baseline hemoglobin, initial ART regimen, and adherence behavior.
  • CONCLUSION: Commonly used definitions for immunologic treatment failure are associated with elevated mortality risk among patients on ART.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2001 May 1;183(9):1328-35 [11294663.001]
  • [Cites] Int J Epidemiol. 2009 Jun;38(3):746-56 [19223334.001]
  • [Cites] Lancet. 2003 Aug 30;362(9385):679-86 [12957089.001]
  • [Cites] Ann Intern Med. 2004 Feb 17;140(4):256-64 [14970148.001]
  • [Cites] Clin Infect Dis. 2005 Aug 1;41(3):376-85 [16007536.001]
  • [Cites] AIDS. 2006 Jan 2;20(1):41-8 [16327318.001]
  • [Cites] AIDS. 2006 Feb 14;20(3):371-7 [16439870.001]
  • [Cites] Lancet. 2006 Apr 22;367(9519):1335-42 [16631912.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1613-9 [16868442.001]
  • [Cites] JAMA. 2006 Aug 16;296(7):782-93 [16905784.001]
  • [Cites] Antivir Ther. 2007;12(1):83-8 [17503751.001]
  • [Cites] JAMA. 2007 Oct 24;298(16):1888-99 [17954540.001]
  • [Cites] PLoS Med. 2007 Oct 16;4(10):e298 [17941716.001]
  • [Cites] AIDS. 2008 Jul 11;22(11):1305-12 [18580610.001]
  • [Cites] BMC Infect Dis. 2008;8:89 [18601727.001]
  • [Cites] AIDS Res Hum Retroviruses. 2008 Aug;24(8):1031-5 [18724803.001]
  • [Cites] AIDS. 2008 Oct 1;22(15):1971-7 [18784460.001]
  • [Cites] AIDS. 2008 Nov 12;22(17):2291-302 [18981768.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):477-84 [18989232.001]
  • [Cites] AIDS. 2009 Mar 27;23(6):697-700 [19209067.001]
  • [Cites] Am J Epidemiol. 2001 Feb 15;153(4):386-93 [11207157.001]
  • (PMID = 19546812.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI027767; United States / NIAID NIH HHS / AI / K23 AI052481-05; United States / PHS HHS / / U62/CCU12354; United States / FIC NIH HHS / TW / D43 TW001035-10; United States / FIC NIH HHS / TW / TW001035-10; United States / FIC NIH HHS / TW / TW006670-01A1; United States / NIAID NIH HHS / AI / AI027767-18; United States / NIAID NIH HHS / AI / P30 AI027767-18; United States / FIC NIH HHS / TW / K01 TW006670-01A1; United States / NIAID NIH HHS / AI / AI052481-05; United States / NIAID NIH HHS / AI / K23-AI01411; United States / FIC NIH HHS / TW / K01 TW006670; United States / FIC NIH HHS / TW / D43 TW001035; United States / NIAID NIH HHS / AI / P30-AI027767; United States / FIC NIH HHS / TW / K01-TW06670
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS139780; NLM/ PMC2734950
  •  go-up   go-down


8. Anastos K, Shi Q, French AL, Levine A, Greenblatt RM, Williams C, DeHovitz J, Delapenha R, Hoover DR: Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr; 2004 Apr 1;35(4):383-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy.
  • BACKGROUND: Total lymphocyte count (TLC) and hemoglobin level have been suggested as useful and inexpensive parameters to indicate need for HAART in settings in which CD4 cell counts are unavailable.
  • If delayed-type hypersensitivity (DTH) response predicts clinical response in persons using highly active antiretroviral therapy (HAART), it may also prove useful in resource-poor settings.
  • OBJECTIVE: To examine whether TLC, hemoglobin, and DTH response observed prior to initiation of HAART predict post-HAART clinical response.
  • MEASUREMENTS: TLC, hemoglobin, CD4 cell counts, and DTH testing using mumps, candida, and tetanus toxoid antigens, performed within 1 year prior to HAART initiation; death; self-report of initiation of HAART use and AIDS-defining illness (ADI).
  • TLC < 850, TLC < 1250, CD4 < 200 cells/microL, anergy to DTH testing, hemoglobin < 10.6 g/dL, and a pre-HAART report of ADI were each consistently independently associated both with death and with incident ADI.
  • CONCLUSIONS: Pre-HAART TLC, hemoglobin level, anergy to DTH testing, and clinical disease each independently predicted morbidity and death after HAART initiation.
  • These findings support the use of TLC to guide decision-making for HAART initiation and suggest that further study of TLC, hemoglobin level, and DTH responses as an indication to provide HAART may be useful in resource-limited settings.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / physiopathology. Hemoglobins. Hypersensitivity, Delayed. Lymphocyte Count
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / physiopathology. Adult. Cohort Studies. Disease Progression. Drug Administration Schedule. Female. Humans. Middle Aged. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15097155.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR-00079; United States / NCRR NIH HHS / RR / M01-RR-00083; United States / NIAID NIH HHS / AI / N01-AI-35161; United States / NIAID NIH HHS / AI / U01-AI-31834; United States / NIAID NIH HHS / AI / U01-AI-34989; United States / NIAID NIH HHS / AI / U01-AI-34993; United States / NIAID NIH HHS / AI / U01-AI-34994; United States / NIAID NIH HHS / AI / U01-AI-35004; United States / NIAID NIH HHS / AI / U01-AI-42590; United States / NICHD NIH HHS / HD / U01-HD-32632
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


9. Gladwin MT, Crawford JH, Patel RP: The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med; 2004 Mar 15;36(6):707-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation.
  • Recent data implicate a critical function for hemoglobin and the erythrocyte in regulating the activity of NO in the vascular compartment.
  • Intravascular hemolysis releases hemoglobin from the red blood cell into plasma (cell-free plasma hemoglobin), which is then able to scavenge endothelium-derived NO 600-fold faster than erythrocytic hemoglobin, thereby disrupting NO homeostasis.
  • This may lead to vasoconstriction, decreased blood flow, platelet activation, increased endothelin-1 expression (ET-1), and end-organ injury, thus suggesting a novel mechanism of disease for hereditary and acquired hemolytic conditions such as sickle cell disease and cardiopulmonary bypass.
  • Furthermore, therapy with NO gas inhalation or infusion of sodium nitrite during hemolysis may attenuate this disruption in vasomotor balance by oxidizing plasma cell-free hemoglobin, thereby preventing the consumption of endogenous NO and the associated pathophysiological changes.
  • In addition to providing an NO scavenging role in the physiological regulation of NO-dependent vasodilation, hemoglobin and the erythrocyte may deliver NO as the hemoglobin deoxygenates.
  • While this process has previously been ascribed to S-nitrosated hemoglobin, recent data from our laboratories suggest that deoxygenated hemoglobin reduces nitrite to NO and vasodilates the human circulation along the physiological oxygen gradient.
  • This newly described role of hemoglobin as a nitrite reductase is discussed in the context of blood flow regulation, oxygen sensing, and nitrite-based therapeutics.
  • [MeSH-minor] Anemia, Hemolytic / therapy. Anoxia / metabolism. Biological Availability. Erythrocyte Membrane / metabolism. Hemolysis. Humans. Nitrite Reductases / metabolism. Vasodilation / drug effects. Vasodilation / physiology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14990351.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL70146
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Nitrites; 31C4KY9ESH / Nitric Oxide; EC 1.7.- / Nitrite Reductases
  • [Number-of-references] 86
  •  go-up   go-down


10. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ, Viral Activation Transfusion Study Investigators: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med; 2001 Jul 3;135(1):17-26
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
  • BACKGROUND: Mortality and morbidity related to AIDS have decreased among HIV-infected patients taking highly active anti-retroviral therapy (HAART), but previous studies may have been confounded by other changes in treatment.
  • PATIENTS: 528 HIV-infected patients with cytomegalovirus (CMV) seropositivity or disease who were receiving a first red blood cell transfusion for anemia.
  • MEASUREMENTS: In a person-year analysis of follow-up before and after initiation of HAART, Poisson regression was used to calculate crude rate ratios and rate ratios adjusted for CD4 count, HIV RNA level, calendar period, time on study, sex, ethnicity, and injection drug use.
  • RESULTS: At baseline, patients had a median CD4(+) lymphocyte count of 0.015 x 10(9) cell/L, median plasma HIV RNA level of 4.8 log(10) copies/mL, and median hemoglobin concentration of 73 g/L.
  • Rates of non-CMV disease were 0.15 event/ person-year after HAART and 0.45 event/person-year before HAART (crude rate ratio, 0.34 [ P < 0.001]; adjusted rate ratio, 0.66 [ P < 0.05]).
  • Rates of CMV disease were 0.10 event/person-year after HAART and 0.25 before HAART (crude rate ratio, 0.42 [ P < 0.01]; adjusted rate ratio, 1.01 [ P > 0.2]).
  • CONCLUSIONS: The data support an independent reduction in mortality and opportunistic events attributable to HAART, even in patients with very advanced HIV disease.
  • However, patients with CMV infection or disease may not have a reduction in new CMV events due to HAART.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Anemia / complications. Anemia / therapy. CD4 Lymphocyte Count. Cytomegalovirus Infections / complications. Double-Blind Method. Erythrocyte Transfusion. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. RNA, Viral / blood. Treatment Outcome. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11434728.001).
  • [ISSN] 0003-4819
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HB / N01-HB-57121
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


11. Castaneda F, Li R, Young K, Swischuk JL, Smouse B, Brady T: Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study. J Vasc Interv Radiol; 2002 Jun;13(6):577-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data, including complications such as bleeding, need for transfusions, and laboratory values (fibrinogen, platelets, hematocrit, hemoglobin, and prothrombin time) were obtained throughout the infusions.
  • The total infusion time ranged from 0.3 to 84 hours (median, 29 h).
  • The lowest fibrinogen level during the procedure was 252.3 mg/dL (range, 35 to >700).
  • Thrombolytic failures occurred in two patients: one with acquired immune deficiency syndrome in a hypercoagulable state and one with a major bleeding complication.
  • CONCLUSION: Although there are reports of thrombolytic therapy in peripheral vascular occlusive disease, this study is one of the first to evaluate thrombolytic drugs in the deep venous system exclusively.
  • Reteplase was found to be effective in the thrombolytic treatment of acute and chronic DVT.
  • [MeSH-major] Catheterization / adverse effects. Fibrinolytic Agents / therapeutic use. Recombinant Proteins / therapeutic use. Thrombolytic Therapy / adverse effects. Tissue Plasminogen Activator / therapeutic use. Venous Thrombosis / drug therapy

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12050297.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Recombinant Proteins; 133652-38-7 / reteplase; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


12. Moore RD, Forney D: Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr; 2002 Jan 1;29(1):54-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia in HIV-infected patients receiving highly active antiretroviral therapy.
  • BACKGROUND: Anemia is common in HIV infection, particularly in advanced disease states.
  • We wished to determine how highly active antiretroviral therapy (HAART) and other factors affected the level of hemoglobin in HIV infection.
  • Analyses were done of hemoglobin levels obtained at baseline and during 1 year of follow-up in patients who received and did not receive a HAART regimen.
  • RESULTS: Eleven percent of patients had a hemoglobin count <10 g/dL, 27% had a hemoglobin count 10 to 12 g/dL, and 21% had a hemoglobin count of >14 g/dL at baseline before HAART was started.
  • During 1 year of follow-up, use of HAART was associated with a hemoglobin levels >14 g/dL in 42% of patients, irrespective of use of zidovudine as part of HAART regimen, compared with 31% of patients who did not use HAART.
  • In multivariate analysis, use of HAART was strongly associated with not having anemia during 1 year of follow-up, adjusting for patient gender, race, injection drug use history, baseline CD4 and HIV-1 RNA levels, and anemia treatments.
  • CONCLUSIONS: HAART is an effective treatment of the anemia of HIV infection.
  • [MeSH-major] Anemia / complications. Anti-HIV Agents / therapeutic use. HIV Infections / complications. HIV-1
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Cohort Studies. Confidence Intervals. Drug Therapy, Combination. Female. Hemoglobins / analysis. Humans. Male. Odds Ratio. Prevalence

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11782590.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R01-DA-11602
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Hemoglobins
  •  go-up   go-down


13. Gupta A, Gupte N, Bhosale R, Kakrani A, Kulkarni V, Nayak U, Thakar M, Sastry J, Bollinger RC, Byramji Jeejeebhoy Medical College-Johns Hopkins University Study Group: Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy. J Acquir Immune Defic Syndr; 2007 Nov 1;46(3):338-42
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy.
  • BACKGROUND: Some studies support the use of total lymphocyte count (TLC) as a surrogate marker for CD4 cell count to guide antiretroviral therapy (ART) initiation.
  • METHODS: CD4, TLC, and hemoglobin were measured at third trimester, delivery, and 6, 9, and 12 months postpartum (PP) in a cohort of 779 HIV-infected women.
  • The sensitivity of TLC <1200 cells/mm3 cutoff ranged between 57% and 62% for time points evaluated.
  • Addition of hemoglobin <12 g/dL or <11 g/dL increased the sensitivity of TLC to 74% to 92% for predicting CD4 <200 cells/mm3 but decreased the specificity to 33% to 69% compared to TLC alone.
  • A combination of TLC, hemoglobin, and WHO clinical staging had the highest sensitivity but lowest specificity compared to other possible combinations or use of TLC alone.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. HIV Infections / drug therapy. Infectious Disease Transmission, Vertical / prevention & control. Lymphocyte Count. Pregnancy Complications, Infectious / drug therapy
  • [MeSH-minor] Adolescent. Adult. Biomarkers. CD4 Lymphocyte Count. Female. Humans. Postpartum Period. Predictive Value of Tests. Pregnancy. Puerperal Disorders / drug therapy. Puerperal Disorders / virology. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846559.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / 2D43TW00010-20-AITRP; United States / NIAID NIH HHS / AI / R01 AI45462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers
  •  go-up   go-down


14. Levine AM, Berhane K, Masri-Lavine L, Sanchez M, Young M, Augenbraun M, Cohen M, Anastos K, Newman M, Gange SJ, Watts H: Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr; 2001 Jan 1;26(1):28-35
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 37% of HIV-positive women and 17% of HIV-negative women had hemoglobin levels < 12 g/dl (p < .001).
  • These data indicate that worsening parameters of HIV disease are associated with anemia among HIV-infected women.
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-HIV Agents / pharmacology. Anti-HIV Agents / therapeutic use. CD4 Lymphocyte Count. Cohort Studies. Cross-Sectional Studies. Disease Progression. Female. HIV Seropositivity / complications. HIV Seropositivity / drug therapy. HIV Seropositivity / immunology. HIV Seropositivity / virology. HIV-1 / drug effects. HIV-1 / genetics. HIV-1 / physiology. Hemoglobins / analysis. Humans. Middle Aged. Multivariate Analysis. Odds Ratio. Prevalence. RNA, Viral / analysis. RNA, Viral / genetics. Reverse Transcriptase Inhibitors / pharmacology. Reverse Transcriptase Inhibitors / therapeutic use. Zidovudine / pharmacology. Zidovudine / therapeutic use

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Women and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11176266.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / UO1-AI-31834; United States / NIAID NIH HHS / AI / UO1-AI-34994; United States / NIAID NIH HHS / AI / UO1-AI-35004
  • [Publication-type] Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Hemoglobins; 0 / RNA, Viral; 0 / Reverse Transcriptase Inhibitors; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


15. Semba RD, Shah N, Vlahov D: Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr; 2001 Apr 1;26(4):315-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy.
  • Although anemia is common during HIV infection, it is unclear whether potent antiretroviral therapy would improve or worsen anemia.
  • We conducted a study to examine the impact of highly active antiretroviral therapy (HAART) on anemia in a cohort of HIV-positive injection drug users (IDUs) in Baltimore, Maryland.
  • During mean follow-up of one year, among 102 subjects who received HAART, there was a mean increase in hemoglobin of 3.6 +/- 1.7 g/L (p =.0003) [corrected] and a mean decrease in log(10) plasma HIV load of 0.25 +/- 0.06 copies/ml (p <.0002) [corrected].
  • Among 103 control subjects who were not receiving antiretroviral medications, there was a mean decrease in hemoglobin of 4.2 +/- 1.1 g/L (p <.04) [corrected] and mean increase in log(10) plasma HIV load of 0.78 +/- 0.17 copies/ml (p <.0001) [corrected].
  • Multivariate analysis using mixed linear models showed that HAART was associated with an increase of hemoglobin of 0.223 g/L per month (p <.0001) after adjusting for body mass index, opportunistic infections, and gender.
  • HAART was associated with an improvement in anemia, and potential mechanisms that may be involved include a reduction in opportunistic infections and the anemia of chronic disease and an improvement in nutritional status.
  • [MeSH-major] Anemia / complications. Anemia / drug therapy. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. Substance Abuse, Intravenous / complications
  • [MeSH-minor] AIDS-Related Opportunistic Infections / blood. AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / virology. Adult. Baltimore. Body Mass Index. CD4 Lymphocyte Count. Chronic Disease. Female. HIV-1 / drug effects. HIV-1 / physiology. Hemoglobins / analysis. Humans. Longitudinal Studies. Male. Multivariate Analysis. Prevalence. Sex Factors. Viral Load

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Acquir Immune Defic Syndr 2002 Aug 1;30(4):462
  • (PMID = 11317071.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI41956; United States / NIDA NIH HHS / DA / DA04334; United States / NIDA NIH HHS / DA / DA08009; United States / NIDA NIH HHS / DA / DA10252
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Hemoglobins
  •  go-up   go-down






Advertisement